Stock Events

Stock Events

AC Immune SA 

$2.51
47
-$0.02-0.97% 12:01 Today

Statistics

Day High
2.54
Day Low
2.52
52W High
4
52W Low
2.03
Volume
3,721
Avg. Volume
-
Mkt Cap
257.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.26
-0.17
-0.07
0.02
Expected EPS
-0.1992090688
Actual EPS
N/A

Financials

-1,971.65%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.5MRevenue
-88.78MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACIU. It's not an investment recommendation.
Apple
9
AAPL
Amazon
9
AMZN
Microsoft
8
MSFT
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen focuses on neurodegenerative diseases, directly competing with AC Immune's Alzheimer's and Parkinson's disease programs.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has advanced Alzheimer's disease treatments in its pipeline, making it a direct competitor in the neurodegenerative disease space.
Roche
RHHBY
Mkt Cap334.28B
Roche, with its strong focus on neuroscience and Alzheimer's disease treatments, competes in the same therapeutic areas as AC Immune.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a history of developing treatments for Alzheimer's disease, positioning it as a competitor despite shifting focus in recent years.
Novartis
NVS
Mkt Cap286.78B
Novartis has a broad portfolio that includes treatments for neurodegenerative diseases, competing with AC Immune's research and development focus.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie's interest in neurodegenerative diseases, including Alzheimer's and Parkinson's, places it in competition with AC Immune.
Merck
MRK
Mkt Cap335.14B
Merck has been involved in developing treatments for Alzheimer's disease, making it a competitor in the neurodegenerative space.
AnaptysBio
ANAB
Mkt Cap1.73B
AnaptysBio, while focusing on inflammation, also explores treatments for neurodegenerative diseases, positioning it as a competitor.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals' work on RNA-targeted therapies includes neurodegenerative diseases, making it a competitor in the same research area.

About

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Show more...
CEO
Martin Zügel
Employees
122
Country
Switzerland
ISIN
CH0329023102
WKN
000A2AR5F

Listings

STU
DE
IMR.STU
MU
DE
IMR.MU
F
DE
IMR.F
XNAS
US
ACIU

0 Comments

Share your thoughts

FAQ

What is AC Immune SA stock price today?▼
The current price of ACIU is $2.51 USD — it has decreased by -0.97% in the past 24 hours. Watch AC Immune SA stock price performance more closely on the chart.
What is AC Immune SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange AC Immune SA stocks are traded under the ticker ACIU.
Is AC Immune SA stock price growing?▼
ACIU stock has fallen by -0.39% compared to the previous week, the month change is a +15% rise, over the last year AC Immune SA has showed a +17.67% increase.
What is AC Immune SA market cap?▼
Today AC Immune SA has the market capitalization of 257.49M
When is the next AC Immune SA earnings date?▼
AC Immune SA is going to release the next earnings report on November 10, 2026.
What were AC Immune SA earnings last quarter?▼
ACIU earnings for the last quarter are 0.02 USD per share, whereas the estimation was -0.1 USD resulting in a +119.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AC Immune SA revenue for the last year?▼
AC Immune SA revenue for the last year amounts to 4.5M USD.
What is AC Immune SA net income for the last year?▼
ACIU net income for the last year is -88.78M USD.
How many employees does AC Immune SA have?▼
As of August 18, 2026, the company has 122 employees.
In which sector is AC Immune SA located?▼
AC Immune SA operates in the Health & Wellness sector.
When did AC Immune SA complete a stock split?▼
AC Immune SA has not had any recent stock splits.
Where is AC Immune SA headquartered?▼
AC Immune SA is headquartered in Lausanne, Switzerland.